|
|
|
|
| LEADER |
02497nam a22003135i 4500 |
| 001 |
000279723 |
| 005 |
20210622104855.0 |
| 007 |
cr nn 008mamaa |
| 008 |
150821s2015 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781493925438
|
| 024 |
7 |
|
|a 10.1007/978-1-4939-2543-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Biobetters :
|b Protein Engineering to Approach the Curative /
|c edited by Amy Rosenberg, Barthélemy Demeule.
|
| 250 |
|
|
|a 1st ed. 2015.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2015.
|
| 300 |
|
|
|a XV, 378 p. 50 illus., 22 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a AAPS Advances in the Pharmaceutical Sciences Series,
|v 19
|
| 505 |
0 |
|
|a Introduction -- Targeting glucocerebrosidase to macrophages for effective treatment of patients with Gaucher disease: setting the paradigm of a "fit for purpose" approach to enzyme replacement therapy -- Challenges of Enzyme Replacement Therapy: Poor tissue distribution in lysosomal diseases using Pompe disease as a model -- Muscle targeting -- Blood-Brain Barrier Targeting of Therapeutic Lysosomal Enzymes -- Novel Methods for Addressing Immunogenicity in Therapeutic Enzymes -- Structure of monoclonal antibodies -- Prediction of aggregation in vivo by studies of therapeutic proteins in human plasma -- Effect of Hydrolytic Degradation on the In Vivo Properties of Monoclonal Antibodies -- Oxidation of proteins in the in-vivo environment: what we know; what we need to study and potential mitigation strategies -- Molecular assessment: balancing affinity, PK and manufacturability -- Perspectives on engineering biobetter therapeutic proteins with greater stability in inflammatory environments -- Antibody-like molecules designed for superior targeting and pharmacokinetics -- Alternative protein scaffolds as novel biotherapeutics -- Current strategies for pharmacokinetic optimization -- Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect? -- Regulatory considerations for approval of biobetter products.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
1 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 650 |
2 |
4 |
|a Biomedicine, general.
|
| 700 |
1 |
|
|a Rosenberg, Amy.
|e editor.
|
| 700 |
1 |
|
|a Demeule, Barthélemy.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|